These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
493 related articles for article (PubMed ID: 22245431)
1. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation. Chandramohan Reddy T; Bharat Reddy D; Aparna A; Arunasree KM; Gupta G; Achari C; Reddy GV; Lakshmipathi V; Subramanyam A; Reddanna P Toxicol In Vitro; 2012 Apr; 26(3):396-405. PubMed ID: 22245431 [TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Zhang GS; Liu DS; Dai CW; Li RJ Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520 [TBL] [Abstract][Full Text] [Related]
3. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230 [TBL] [Abstract][Full Text] [Related]
4. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Kurosu T; Ohki M; Wu N; Kagechika H; Miura O Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808 [TBL] [Abstract][Full Text] [Related]
5. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Rahmani M; Nguyen TK; Dent P; Grant S Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571. Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011 [TBL] [Abstract][Full Text] [Related]
7. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells. Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463 [TBL] [Abstract][Full Text] [Related]
8. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Yu C; Krystal G; Dent P; Grant S Clin Cancer Res; 2002 Sep; 8(9):2976-84. PubMed ID: 12231544 [TBL] [Abstract][Full Text] [Related]
9. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536 [TBL] [Abstract][Full Text] [Related]
10. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP. Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346 [TBL] [Abstract][Full Text] [Related]
11. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta. Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834 [TBL] [Abstract][Full Text] [Related]
12. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1. Li QF; Yan J; Zhang K; Yang YF; Xiao FJ; Wu CT; Wang H; Wang LS Biochem Biophys Res Commun; 2011 Feb; 405(1):31-6. PubMed ID: 21195056 [TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976 [TBL] [Abstract][Full Text] [Related]
14. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells. Okabe S; Tauchi T; Ohyashiki K Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496 [TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells. Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377 [TBL] [Abstract][Full Text] [Related]
16. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion. Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107 [TBL] [Abstract][Full Text] [Related]
17. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Rahmani M; Reese E; Dai Y; Bauer C; Kramer LB; Huang M; Jove R; Dent P; Grant S Mol Pharmacol; 2005 Apr; 67(4):1166-76. PubMed ID: 15625278 [TBL] [Abstract][Full Text] [Related]
18. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456 [TBL] [Abstract][Full Text] [Related]
19. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway. Wei YL; Liang Y; Xu L; Zhao XY Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]